PPARα and PPARδ activators inhibit cytokine-induced nuclear translocation of NF-κB and expression of VCAM-1 in EAhy926 endothelial cells
…, T Taillandier, M Pezet, E Dupont-Passelaigue… - European journal of …, 2002 - Elsevier
Endothelium injury is a primary event in atherogenesis, which is followed by monocyte infiltration,
macrophage differentiation, and smooth muscle cell migration. Peroxisome proliferator-…
macrophage differentiation, and smooth muscle cell migration. Peroxisome proliferator-…
F 11440, a Potent, Selective, High Efficacy 5-HT1AReceptor Agonist with Marked Anxiolytic and Antidepressant Potential
…, E Dupont-Passelaigue, E Carilla-Durand… - … of Pharmacology and …, 1998 - ASPET
F 11440 (4-methyl-2-[4-(4-(pyrimidin-2-yl)-piperazino)-butyl]-2H,4H-1,2,4-triazin-3,5-dione)
was the outcome of a research effort guided by the hypothesis that the magnitude of the …
was the outcome of a research effort guided by the hypothesis that the magnitude of the …
Human adipocyte fatty acid-binding protein (aP2) gene promoter-driven reporter assay discriminates nonlipogenic peroxisome proliferator-activated receptor γ ligands
…, C Cathala, F Lestienne, E Dupont-Passelaigue… - … of Pharmacology and …, 2004 - ASPET
Peroxisome proliferator-activated receptors (PPARs) regulate storage and catabolism of fats
and carbohydrates. PPARγ activity increases insulin sensitivity and adipocyte differentiation …
and carbohydrates. PPARγ activity increases insulin sensitivity and adipocyte differentiation …
Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages
…, F Lestienne, E Dupont-Passelaigue… - DNA and cell …, 2004 - liebertpub.com
It is now recognized that atherosclerosis complications are related to the unstable character
of the plaque rather than its volume. Vulnerable plaques often contain a large lipid core, a …
of the plaque rather than its volume. Vulnerable plaques often contain a large lipid core, a …
PPAR activators and COX inhibitors selectively block cytokine-induced COX-2 expression and activity in human aortic smooth muscle cells
…, F Lestienne, E Dupont-Passelaigue… - European journal of …, 2009 - Elsevier
Atherosclerotic complications are related to the unstable character of the plaque rather than
its volume. Vulnerable plaques often contain a large lipid core, a reduced content of smooth …
its volume. Vulnerable plaques often contain a large lipid core, a reduced content of smooth …
F 16915 prevents heart failure-induced atrial fibrillation: a promising new drug as upstream therapy
B Le Grand, R Letienne, E Dupont-Passelaigue… - Naunyn-Schmiedeberg's …, 2014 - Springer
Atrial fibrillation (AF) is a common complication of heart failure. The aim of the present study
was to investigate the effects of a new pure docosahexaenoic acid derivative called F 16915 …
was to investigate the effects of a new pure docosahexaenoic acid derivative called F 16915 …
[CITATION][C] HUMAN aP2 GENE PROMOTER-DRIVEN REPORTER ASSAY DISCRIMINATES NON-LIPOGENIC PPARγ LIGANDS
…, C Cathala, F Lestienne, E Dupont-Passelaigue… - … of Pharmacology and …, 2004 - ASPET
Peroxisome proliferator-activated receptors (PPARs) regulate storage and catabolism of fats
and carbohydrates. PPARγ activity increases insulin sensitivity and adipocyte differentiation …
and carbohydrates. PPARγ activity increases insulin sensitivity and adipocyte differentiation …
[CITATION][C] PPARa and PPARd inhibitors inhibit cytokine-induced nuclear translocation of NF-kB and expression of VCAM-1 in EAhy926 endothelial cells
…, T Taillandier, M Pezet, E Dupont-Passelaigue… - Eur. J. Pharmacol, 2002
[CITATION][C] Preparation of N-[(4-substituted piperazin-1-yl) carbonyl]-heteroaryl sulfonamides and analogs as Kv potassium channel blockers
E Dupont-Passelaigue, I Le Roy, C Pignier - WO069503, 2012
[CITATION][C] Patoiseau 922 JF, Junquéro D, Colpaert FC, Delhon A
…, T Taillandier, M Pezet, E Dupont-Passelaigue - PPARα and PPARδ activators …